Can Operating Margin from 2010 to 2026
| CANF Stock | USD 4.05 0.08 1.94% |
Check Can Fite financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Can Fite's main balance sheet or income statement drivers, such as Depreciation And Amortization of 6 K, Interest Expense of 12 K or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 18.39, Dividend Yield of 0.0 or PTB Ratio of 2.95. Can financial statements analysis is a perfect complement when working with Can Fite Valuation or Volatility modules.
Can | Operating Margin | Build AI portfolio with Can Stock |
The Operating Margin trend for Can Fite Biopharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Can Fite is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Can Fite's Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Can Fite Biopharma over the last few years. It is Can Fite's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Can Fite's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (24.25) % | 10 Years Trend |
|
Operating Profit Margin |
| Timeline |
Can Operating Margin Regression Statistics
| Arithmetic Mean | (19.38) | |
| Coefficient Of Variation | (79.13) | |
| Mean Deviation | 12.92 | |
| Median | (12.06) | |
| Standard Deviation | 15.33 | |
| Sample Variance | 235.08 | |
| Range | 49.5199 | |
| R-Value | 0.40 | |
| Mean Square Error | 211.43 | |
| R-Squared | 0.16 | |
| Significance | 0.12 | |
| Slope | 1.20 | |
| Total Sum of Squares | 3,761 |
Can Operating Margin History
About Can Fite Financial Statements
Can Fite stakeholders use historical fundamental indicators, such as Can Fite's Operating Margin, to determine how well the company is positioned to perform in the future. Although Can Fite investors may analyze each financial statement separately, they are all interrelated. For example, changes in Can Fite's assets and liabilities are reflected in the revenues and expenses on Can Fite's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Can Fite Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel. Can-Fite Biopharma operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 8 people.
Currently Active Assets on Macroaxis
When determining whether Can Fite Biopharma is a strong investment it is important to analyze Can Fite's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Can Fite's future performance. For an informed investment choice regarding Can Stock, refer to the following important reports:Check out the analysis of Can Fite Correlation against competitors. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Can Biotechnology industry sustain growth momentum? Does Can have expansion opportunities? Factors like these will boost the valuation of Can Fite. Projected growth potential of Can fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Can Fite demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding Can Fite Biopharma requires distinguishing between market price and book value, where the latter reflects Can's accounting equity. The concept of intrinsic value—what Can Fite's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Can Fite's price substantially above or below its fundamental value.
It's important to distinguish between Can Fite's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Can Fite should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Can Fite's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.